Diseases caused by the pneumococcus represent the largest cause of vaccine preventable death in the world today, mainly pneumonia and meningitis. In 2011, 16 developing countries will introduce pneumococcal conjugate vaccines, none in east Asia. Lack of research has been a major barrier to their use in the region. We have established an international centre of excellence in the field and we seek support to extend the capacity of this group and to transfer the technology to Vietnam.
Immunogenicity Of 23-valent Pneumococcal Polysaccharide Vaccination Among Indigenous Australian Adolescents And Adults
Funder
National Health and Medical Research Council
Funding Amount
$674,738.00
Summary
Multiple doses of pneumococcal vaccine are recommended for Indigenous Australians under a unique schedule aimed at reducing high rates of pneumococcal disease. However, disease rates have not reduced after several years of the program. This study examines a key, previously unstudied explanation for the lack of disease reduction in this population: that repeated vaccination could produce suboptimal protection against disease. It will provide evidence to underpin future vaccination policy.
Asia-Pacific Pneumococcal Disease Control In The Pneumococcal Conjugate Vaccine Era
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
Pneumonia is one of the commonest causes of childhood death worldwide. PCV is a vaccine that prevents pneumonia but it is costly; and causes an increase in disease from strains which are not in the vaccine. Our CRE will address 2 outstanding issues: when to switch from a 3 to 2 dose PCV schedule to make it more affordable; and create new understanding of the non-vaccine strains’ impact on disease in low- and middle-income countries in the Asia-Pacific region.
A Serotype-independent, Broad Spectrum Pneumococcal Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$955,585.00
Summary
Streptococcus pneumoniae (the pneumococcus) is the world’s most formidable bacterial pathogen, causing 1-2 million deaths each year. Existing vaccines provide protection against only a limited proportion of strains and their widespread use is increasing the prevalence of strains against which the vaccines provide no protection. This project aims to translate a novel broadly protective pneumococcal vaccine into the commercial development pipeline.
Evaluation Of The Effectiveness Of The 13-valent Pneumococcal Conjugate Vaccine On Pneumococcal Serotypes Causing Pneumonia In Children
Funder
National Health and Medical Research Council
Funding Amount
$1,137,532.00
Summary
Streptococcus pneumonia (Pneumococcus) is a bug that is a leading cause of childhood morbidity and mortality world-wide. Vaccinations have been recently brought onto the national immunisation program to try and combat this. This study aims to assess the new 13 valent Pneumococcal vaccine by studying its effectiveness in preventing childhood pneumonia in Australia by analysing the strains of Pneumococus in the blood and the fluid surrounding the lining the lung in complicated pneumonia using sens ....Streptococcus pneumonia (Pneumococcus) is a bug that is a leading cause of childhood morbidity and mortality world-wide. Vaccinations have been recently brought onto the national immunisation program to try and combat this. This study aims to assess the new 13 valent Pneumococcal vaccine by studying its effectiveness in preventing childhood pneumonia in Australia by analysing the strains of Pneumococus in the blood and the fluid surrounding the lining the lung in complicated pneumonia using sensitive molecular techniques.Read moreRead less
Reducing The Community Burden Of Respiratory Infections In Indigenous Children
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Lower respiratory infections are the leading cause of preventable mortality among Indigenous children in the Northern Territory. Streptococcus pneumoniae remain one of the major paediatric respiratory pathogens. In this proposal I will describe the impact of past and present pneumococcal vaccination strategies on the burden of infant respiratory infections in this region.
Pneumococcal disease is one of the biggest killers of children under 5 years of age worldwide, mostly in developing countries. Pneumococcal conjugate vaccines are highly effective at reducing pneumococcal disease however the duration of protection and the immune factors involved is unknown, particularly when fewer than the recommended number of doses are used. My fellowship aims to examine the key immune factors that provide long-term protection following pneumococcal vaccination.
Comparing Pneumococcal Vaccines In A High Risk Population: A Randomised Controlled Trial Of Immunogenicity, Safety And Impact On Carriage Of Pneumococcal Conjugate And Polysaccharide Vaccines In Infants In Papua New Guinea
Funder
National Health and Medical Research Council
Funding Amount
$1,042,670.00
Summary
Pneumococcal disease is a major cause of pneumonia and meningitis in infants in developing countries in particular resulting in an estimated 800,000 deaths each year. This project will study how well pneumococcal vaccines perform in 260 high-risk infants in Papua New Guinea. We will examine how well the vaccines stimulate protective immunity and reduce babies carrying the pneumococcal bacteria in their nose and how long this immunity lasts for. The study will inform global immunisation policy.
Impact Of DTP Schedules On The Immunogenicity Of 2 Doses Of 13v-PCV Followed By An Early Booster
Funder
National Health and Medical Research Council
Funding Amount
$2,651,687.00
Summary
This project aims to come up with a vaccination schedule to make pneumococcal vaccines more effective and affordable for Fiji and other developing countries. We will evaluate schedules involving a 2 dose primary series in early infancy with a booster at 9 months of age. We will compare the immune responses to 3 different primary series and 2 booster options. The results of this project will be used to provide advice, at global and country levels, regarding introduction of pneumococcal vaccines.